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Secondary osteoporosis results from medical conditions
or treatments that interfere with the attainment of peak
bone mass and/or may predispose to accelerated bone loss.
Although secondary osteoporosis is less common, it is
becoming more frequently diagnosed. Apart from the well-
deﬁned risk of secondary osteoporosis in patients requiring
long-term corticosteroids therapy, an increasing list of dieta-
ry, lifestyle, endocrine, metabolic, and other causes of bone
mass deterioration has been identiﬁed (Table 1). Recently
it has been demonstrated that, in contrast to primary
osteoporosis which is associated with age, gender, and family
history, secondary osteoporosis shows a prevalence in men
similar to that in women (men 21% versus women 17.5%)
[1]. However, at presentation with a recent clinical vertebral
or nonvertebral fracture, at least 27% of patients have
previouslyunknowncontributorstosecondaryosteoporosis,
w h i c ha r et r e a t a b l eo rn e e df o l l o w - u p[ 2]. Therefore, a
careful medical examination always should be carried out
in each patient with a recent fracture to exclude potentially
reversible causes of bone loss. In comparison with primary
osteoporosis, treatment of secondary osteoporosis is usually
more complex and requires treating the underlying disease.
The main focus of this special issue is on current re-
search that advances our understanding of the mechanisms
underlying the endocrine and metabolic causes of bone mass
deterioration. In the paper “Bone mineral density accrual
determines energy expenditure with refeeding in anorexia
nervosa and supersedes return of menses,” the authors in
the clinical study examined the disproportionate increase in
resting energy expenditure that occurs with refeeding of
womenwithanorexianervosatodetermineifitwasrelatedto
bone mass increase. They found that prolonged nutritional
rehabilitation may lead to recovery from osteopenia (a com-
mon ﬁnding in anorexia nervosa) and resumption of menses
in the women who remain amenorrheic with low bone
mineral density (BMD). The paper entitled “Protective role
of black tea extract (BTE) against non-alcoholic steatohepatitis
(NASH)-induced skeletal dysfunction” was aimed to examine
the chemoprotective actions of aqueous BTE on decreased
BMD induced by nonalcoholic steatohepatitis in the Wistar
rats. Some previous studies have suggested that habitual tea
consumption might have beneﬁcial eﬀect on BMD in adults.
In this study, the authors conﬁrmed this suggestion in rats
and also found that BTE may inﬂuence levels of RANKL,
osteoprotegerin, and bone turnover markers. The paper
“Bone health in patients with multiple sclerosis” describes the
up-to-date diagnostic criteria and includes detailed review
of the common risk factors, pathophysiology, and treatment
options of secondary osteoporosis in patients with multiple
sclerosis. The paper “A roadmap to the brittle bones of
cystic ﬁbrosis” summarizes the current knowledge on the
risk for osteoporosis in this autosomal recessive disorder.
Unlike primary osteoporosis, bone disease in cystic ﬁbrosis
begins at a young age and is associated with signiﬁcant
morbidity due to fractures and decreased lung function. This
paper reviews the pathophysiology, current clinical practice2 Journal of Osteoporosis
Table 1: Causes of secondary osteoporosis.
Dietary
Anorexia nervosa
Excessive protein intake
Excess vitamin A
Inadequate vitamin D intake
Smoking
Excess alcohol intake
Parenteral nutrition
Lifestyle
Low physical activity
Prolonged immobilization
Endocrine
Adrenal insuﬃciency
Cushing’s syndrome
Diabetes mellitus
Hyperthyroidism
Hypogonadism
Hypopituitarism
Pregnancy
Metabolic
Malabsorption syndrome
Chronic metabolic acidosis
Systematic diseases
End-stage renal disease
Primary biliary cirrhosis
Inﬂammatory bowel disease
Cystic ﬁbrosis
Rheumatoid arthritis
Chronic obstructive pulmonary disease
Mastocytosis
Chronic inﬂammation
Surgery/transplantation
Bariatric surgery
Organ transplantation
Medications
Corticosteroids
Antiepileptics
Selective serotonin-reuptake inhibitors
Heparin
guidelines, and future therapies for treating bone disease
associated with cystic ﬁbrosis. Another paper in this issue,
“Are selective serotonin reuptake inhibitors a secondary cause
of decreased bone density?”, deals with severe complication
of therapy with commonly prescribed selective serotonin-
reuptake inhibitors (SSRIs). Although multiple consistent
ﬁndings reveal a trend suggesting that SSRI use may neg-
atively impact bone and result in lower BMD, a deﬁnitive
causal relationship cannot be drawn. However, a growing
body of evidence suggests an association between SSRI use
and bone loss which seems suﬃcient to consider adding
SSRIs to the list of medications that contribute to secondary
osteoporosis. Another review paper in this issue, “Secondary
osteoporosis in patients with juvenile idiopathic arthritis,” fo-
cuses on focal and systemic bone loss seen in juvenile
idiopathic osteoporosis. Several clinical and epidemiological
studies are reviewed in order to highlight putative factors
that may contribute to bone loss in juvenile idiopathic
osteoporosis, including low lean mass, growth retardation,
impact of proinﬂammatory cytokines on bone remodeling,
RANK/RANKL/osteoprotegerin imbalance, and abnormal
Wnt signaling.
The papers presented in this special issue depict some
novel and hitherto not intensively studied aspects of sec-
ondary osteoporosis, underscoring the complexity of mech-
anisms that predispose to bone mass deterioration induced
by metabolic and endocrine risk factors. The editors thank
the authors of all submissions and hope that the content of
this special issue will be useful for clinical practice and future
research.
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